Jun 2025 Articles

Articles
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis
Masson W, Barbagelata L, Lobo M, et al.
Journal:
J Clin Lipidol

First published: June 23, 2025 DOI: 10.1016/j.jacl.2024.12.016
View
- Share
Articles
Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a)
Wulff AB, Nordestgaard BG
Journal:
Eur Heart J

First published: June 16, 2025 DOI: 10.1093/eurheartj/ehaf274
View
- Share
Articles
Colchicine for Secondary Prevention in Established ASCVD: A Systematic Review and Meta-Analysis
Abdelaziz A, Sobhy A, Nazmy A, et al.
Journal:
Eur J Prev Cardiol

First published: June 12, 2025 DOI: 10.1093/eurjpc/zwaf332
View
- Share
Articles
Maturation of Lipid Management in the 2025 ACC/AHA Acute Coronary Syndrome Guideline: What It Is and What It Might Have Been
Brandts J, Ray KK
Journal:
J Am Coll Cardiol

First published: June 10, 2025 DOI: 10.1016/j.jacc.2025.04.024
View
- Share
Articles
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis
Fukami H, Oike Y
Journal:
J Atheroscler Thromb

First published: June 5, 2025 DOI: 10.5551/jat.RV22038
View
- Share
Articles
Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies
Barkas F, Brandts J, De Bacquer D, et al.
Journal:
J Am Coll Cardiol

First published: June 3, 2025 DOI: 10.1016/j.jacc.2025.04.010
View
- Share

Jun 2025 Articles

Articles

Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis

Masson W, Barbagelata L, Lobo M, et al.

Articles

Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a)

Wulff AB, Nordestgaard BG

Articles

Colchicine for Secondary Prevention in Established ASCVD: A Systematic Review and Meta-Analysis

Abdelaziz A, Sobhy A, Nazmy A, et al.

Articles

Maturation of Lipid Management in the 2025 ACC/AHA Acute Coronary Syndrome Guideline: What It Is and What It Might Have Been

Brandts J, Ray KK

Articles

ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis

Fukami H, Oike Y

Articles

Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies

Barkas F, Brandts J, De Bacquer D, et al.

Articles

Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis

Masson W, Barbagelata L, Lobo M, et al.

Share

Articles

Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a)

Wulff AB, Nordestgaard BG

Share

Articles

Colchicine for Secondary Prevention in Established ASCVD: A Systematic Review and Meta-Analysis

Abdelaziz A, Sobhy A, Nazmy A, et al.

Share

Articles

Maturation of Lipid Management in the 2025 ACC/AHA Acute Coronary Syndrome Guideline: What It Is and What It Might Have Been

Brandts J, Ray KK

Share

Articles

ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis

Fukami H, Oike Y

Share

Articles

Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies

Barkas F, Brandts J, De Bacquer D, et al.

Share